Oyster Point Pharma, Inc. announced that the FDA approved Tyrvaya (varenicline solution 0.03 mg) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.

Tyrvaya Nasal Spray is a highly selective cholinergic agonist delivered twice daily as an aqueous nasal spray into each nostril to activate basal tear production.

The spray is available with a prescription this month (November) in cartons containing two multidose nasal spray bottles. Each nasal spray bottle covers treatment for 15 days, administered twice daily into each nostril. Samples that provide 15 days of treatment will also be made available to eye care providers.

The most common adverse reaction reported in 82% of patients was sneezing, Oyster Point Pharma says. OM